Opal Therapeutics Receives $1.25M NSF Investment to Advance Women's Health Organoid Platform
Top Picks
Stay Ahead of the Market
Get the latest startup funding, hiring trends and global opportunities delivered to your inbox every week.
Opal Therapeutics Secures $1.25 Million NSF Investment
San Francisco-based biotechnology company Opal Therapeutics has received a $1.25 million investment from the National Science Foundation (NSF) to accelerate the development of its patient-derived organoid platform for women's reproductive health.
The funding will support the company's efforts to expand laboratory capabilities and advance therapeutic and diagnostic research for chronic gynecological diseases.
Advancing Women's Health Through Organoid Technology
Led by Morgan Stanton, Ph.D., CEO, Opal Therapeutics develops a patient-derived organoid platform designed to improve early-stage drug discovery and diagnostics for women's reproductive health.
The company's technology isolates cells from menstrual blood and surgical biopsies to build a biobank of patient-derived organoid and cellular models that accurately capture disease-specific biological signatures.
Its platform supports research into conditions including:
Endometriosis
Uterine fibroids
Polycystic Ovary Syndrome (PCOS)
Heavy menstrual bleeding
By combining patient tissue data with computational analysis, Opal Therapeutics enables deeper in vitro and in silico insights for pharmaceutical and biotechnology research.
Funding to Expand Research Infrastructure
The NSF investment will be used to:
Scale laboratory infrastructure
Increase patient-derived organoid manufacturing
Expand imaging and inflammation assay capabilities
Grow proprietary biological datasets
These investments aim to strengthen the company's platform for preclinical therapeutic and diagnostic development.
Supporting Drug Discovery
Opal Therapeutics works with pharmaceutical and biotechnology companies to reduce risk during early-stage preclinical discovery by providing more representative human disease models for research and development.
The company operates from San Francisco, California, serving partners focused on advancing treatments for chronic women's health conditions.
Leadership
Opal Therapeutics is led by Morgan Stanton, Ph.D., CEO.
The company is headquartered in San Francisco, California, USA.
